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Available online 22 October 2015This presentation summarisedmany broad principles relating to
management of locally advanced prostate cancer (PC). This is a
group of patients with disease conﬁned to the prostate or pelvic
lymph nodes, is high grade (Gleason Score 8e10) or bulky (cT3-4)
or have a PSA >20 ng/mL. In most centres, the exclusion of meta-
static disease would be done with CT abdomen and pelvis along
with whole body bone scan.
The importance of local therapy in this setting has been deﬁned
through several randomised clinical trials (RCTs). Studies comparing
local therapy in the form of radical prostatectomy with observation
have showna survival beneﬁt eitheroverall or inhigh risk subgroups.
Reinforcing the beneﬁt of local therapy in high risk PC are the two
large RCTs of androgen deprivation therapy (ADT) with or without
radiation therapy (RT) to theprostate. Both of these studies showed a
signiﬁcant survival beneﬁt to having local therapy in addition toADT,
as has been a standard approach for managing men with this con-
dition for several decades1,2 (no RCT data exists to compare radical
prostatectomy to radical radiotherapy). Many RCTs have now been
published to address the issue of the duration of ADT in combination
with RT. In general, longer durations of ADT (in the order of several
years) are more efﬁcacious than shorter durations (3e6 months)
when locallyadvancedorhigh grade cancers are treated. Theoptimal
duration of adjuvant ADT in this setting is, however, still uncertain.
The role of treating the pelvic lymph nodes in locally advanced
PC has similarly been tested in large RCTs. Most recently, two large
studies comparing whole pelvic nodal plus prostate irradiation to
prostate only RT have shown no convincing beneﬁt for nodal RT on
clinical or survival outcomes.3,4 While this is level 1 evidence on no
effect, studies examining altered approaches (such as the addition
of ADT to nodal RT) are ongoing.* Corresponding author: Scott Williams (scott.williams@petermac.org).
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p2287-8882 e2287-903XRecently, interest has increased around the use of more intense
therapy adjuvant to RT. Three RCTs now have explored the use of
docetaxel chemotherapy in combinationwith ADT and RT in locally
advanced PC. These studies have now presented data which shows
a relatively consistent reduction in the risk of relapse, but no
consistent overall survival improvement at this early stage.5e7
Further data is required to fully understand the impact of this
more aggressive approach.
Post-prostatectomy RT (PPRT) is commonly utilised as a com-
bined approach to locally advanced PC. Two RCTs now have been
completed which show clinical beneﬁt, including a survival beneﬁt
in one, to having adjuvant PPRT within 4 months of surgery when
high risk features exist such as pT3 status or surgical margin
positivity.8,9 Despite these data, it is still commonplace to only use
PPRT as salvage therapy for deﬁned recurrence, usually as a rising
PSA. Several studies are running to determine optimal usage of
salvage PPRT such as adjuvant ADT and nodal irradiation.
In health care systems with limited resources, management of
locally advanced PC should be tailored to these issues.
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